Greenphire Announces New London Office to Facilitate Expansion in Europe
Greenphire
, the leading provider of payment technologies for the clinical trials industry, today announced an expansion into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and isdesigned to support the increasing global demand for Greenphire’s products and services.
The expansion reflects the commercial and operational success Greenphire has enjoyed in the last two years. Both global payment technology platforms for Patient and Investigator payments have seen increased adoption within the life sciences industry and the new office in London will play a critical role in continuing to build on the growth Greenphire has experienced.
Sam Whitaker, Founder and CEO, comments “We are excited to execute on this key part of our 2013 strategic plan. Establishing our presence in Europe allows us to support our Enterprise clients in those areas where they conduct research and development, facilitates stronger support of the many clinical investigators conducting research on behalf of biopharmaceutical companies and provides abase from which we can grow our commercial presence in Europe.”
The new UK office address is: Greenphire, 1 EastPoultry Avenue, London, EC1A 9PT, United Kingdom and the London office number is: +44 (0) 208 150 6470
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
